MPN Research Foundation initiates exploratory gene editing project

CRISPR technology to be evaluated for its applicability and safety for blood cancer group myeloproliferative neoplasms.(PRWeb February 12, 2015)Read the full story at http://www.prweb.com/releases/2015/02/prweb12506359.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news